(Abacavir sulfate + lamivudine + lopinavir + ritonavir) is under clinical development by Cipla and currently in Pre-Registration for Human Immunodeficiency Virus (HIV) Infections (AIDS). According to GlobalData, Pre-Registration drugs for Human Immunodeficiency Virus (HIV) Infections (AIDS) have a 96% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how (Abacavir sulfate + lamivudine + lopinavir + ritonavir)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Abacavir sulfate + lamivudine + lopinavir + ritonavir) overview

A fixed dose combination of abacavir sulfate, lamivudine, lopinavir, and ritonavir is under development for the treatment of human immunodeficiency virus (HIV) in infants and children under three years of age. It is an antiretroviral (ARV) formulation for oral administration. The drug candidate acts by targeting HIV 1 retropepsin, HIV 2 retropepsin, reverse transcriptase.

Abacavir sulfate, lamivudine, lopinavir and ritonavir(Quadrimune) is a fixed dose combination, acts as an anti-viral agents. It is formulated as capsules for oral route of administration. Quadrimune indicated for the treatment of hiv-1 infection in children aged ≥ 3 months, weighing ≥3 to ≤19.9kg (who weight band 1 ( wb1), wb 2, wb 3 and wb 4).

Cipla overview

Cipla is a pharmaceutical company, which manufactures and distributes branded medicines, generics and active pharmaceutical ingredients (APIs). It offers products in therapeutic areas such as cardiovascular and pediatric diseases, dermatological and cosmetological conditions, HIV/AIDS, diabetes, hepatitis, infectious diseases and critical care, neurological, ophthalmic, cancer, malaria, respiratory and urological conditions, osteoporosis and women’s health. The company also operates in consumer healthcare and biosimilar businesses. Cipla manufactures metered-dose inhaler devices, spacers and related devices; and conducts R&D to develop new medicines and drug delivery systems. The company has operations in India, US, Canada, South Africa and major regulated and emerging markets among others. Cipla is headquartered in Mumbai, Maharashtra, India.

For a complete picture of (Abacavir sulfate + lamivudine + lopinavir + ritonavir)’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.